US Upholds $70m Hospira Epogen Verdict
Biosimilar Safe Harbors Need Record Of Non-Commercial Use, Ruling Suggests
Executive Summary
Federal Circuit affirms jury's $70m award to Amgen and finding that some Hospira biosimilar batches were not protected by the safe harbor. Decision conveys how biosimilar makers can obtain this protection from infringement suits.